Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNNI3K | Q59H18 | 2/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | BCR | P11274 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | CCR9 | P51686 | 3/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22718278 | 0.88 | CA12 (0.40) | TNNI3KBRAFKDM4EMEN1KMT2A | |
| SCHEMBL22843399 | 0.85 | MAPT (0.45) | TNNI3KBRAFMAPTKDM4EMEN1 | |
| SCHEMBL22843416 | 0.84 | TEAD1 (0.45) | TNNI3KBRAFABL1BCRMAPT | |
| SCHEMBL22843417 | 0.82 | KDM4E (0.37) | TNNI3KBRAFMAPTKDM4EMEN1 | |
| SCHEMBL22843415 | 0.79 | CA2 (0.36) | TNNI3KBRAFMAPTKDM4EMEN1 | |
| SCHEMBL22843423 | 0.79 | CA12 (0.41) | MAPTKDM4ESMN1; SMN2SLC6A4SLC6A3 | |
| SCHEMBL22843501 | 0.79 | IDH1 (0.41) | — | |
| SCHEMBL22843422 | 0.78 | CDK2 (0.36) | TNNI3KBRAFMAPTKDM4EMEN1 | |
| SCHEMBL22843409 | 0.76 | CYP2C9 (0.37) | TNNI3KABL1BCRMAPTKDM4E | |
| SCHEMBL22843472 | 0.76 | KMT2A (0.38) | MAPTKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11760728-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11274082-B2 | Tead inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | THE EHE FOUNDATION | 2020-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11274082-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885BRAF 701/4885ABL1 6/4885 |
| US-11760728-B2 | Tead inhibitors and uses thereof | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885BRAF 701/4885ABL1 6/4885 |
| US-20200407327-A1 | TEAD INHIBITORS AND USES THEREOF | TEAD2, TEAD3, TEAD4 | TNNI3K 129/4885BRAF 701/4885ABL1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.